Cell-penetrating peptides for transmucosal delivery of proteins

被引：23
作者：
Wu, Jiamin [1 ]
Roesger, Sophie [1 ]
Jones, Natalie [1 ]
Hu, Che-Ming J. [2 ]
Li, Shyh-Dar [1 ]
机构：
[1] Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
[2] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan
来源：
JOURNAL OF CONTROLLED RELEASE | 2024年 / 366卷
基金：
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词：
Cell -penetrating peptides (CPPs); Proteins; Peptides; Transmucosal delivery; Intranasal; Buccal and sublingual; Oral; TO-BRAIN DELIVERY; DRUG-DELIVERY; TRANSDUCTION DOMAIN; NASAL DELIVERY; INTRANASAL DELIVERY; GUT MICROBIOTA; BARRIER; ABSORPTION; MECHANISMS; STRATEGIES;
D O I：
10.1016/j.jconrel.2024.01.038
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Enabling non-invasive delivery of proteins across the mucosal barriers promises improved patient compliance and therapeutic efficacies. Cell-penetrating peptides (CPPs) are emerging as a promising and versatile tool to enhance protein and peptide permeation across various mucosal barriers. This review examines the structural and physicochemical attributes of the nasal, buccal, sublingual, and oral mucosa that hamper macromolecular delivery. Recent development of CPPs for overcoming those mucosal barriers for protein delivery is summarized and analyzed. Perspectives regarding current challenges and future research directions towards improving noninvasive transmucosal delivery of macromolecules for ultimate clinical translation are discussed.
引用
收藏
页码：864 / 878
页数：15
相关论文
共 216 条
[1]   Influenza Vaccine for 2019-2020 (Reprinted from Medical Letter on Drugs and Therapeutics, vol 61, pg 161-165, 2019) [J].
Abramowicz, Mark ;
Zuccotti, Gianna ;
Pflomm, Jean-Marie .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (01) :84-85
[2]   Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors [J].
Abramson, Alex ;
Frederiksen, Morten Revsgaard ;
Vegge, Andreas ;
Jensen, Brian ;
Poulsen, Mette ;
Mouridsen, Brian ;
Jespersen, Mikkel Oliver ;
Kirk, Rikke Kaae ;
Windum, Jesper ;
Hubalek, Frantisek ;
Water, Jorrit J. ;
Fels, Johannes ;
Gunnarsson, Stefan B. ;
Bohr, Adam ;
Straarup, Ellen Marie ;
Ley, Mikkel Wennemoes Hvitfeld ;
Lu, Xiaoya ;
Wainer, Jacob ;
Collins, Joy ;
Tamang, Siddartha ;
Ishida, Keiko ;
Hayward, Alison ;
Herskind, Peter ;
Buckley, Stephen T. ;
Roxhed, Niclas ;
Langer, Robert ;
Rahbek, Ulrik ;
Traverso, Giovanni .
NATURE BIOTECHNOLOGY, 2022, 40 (01) :103-+
[3]   Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs [J].
Agrawal, Mukta ;
Saraf, Swarnlata ;
Saraf, Shailendra ;
Antimisiaris, Sophia G. ;
Chougule, Mahavir Bhupal ;
Shoyele, Sunday A. ;
Alexander, Amit .
JOURNAL OF CONTROLLED RELEASE, 2018, 281 :139-177
[4]   Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative [J].
Akita, Tomomi ;
Oda, Yusuke ;
Kimura, Ryosuke ;
Nagai, Mio ;
Tezuka, Ayano ;
Shimamura, Mizuki ;
Washizu, Kaho ;
Oka, Jun-Ichiro ;
Yamashita, Chikamasa .
JOURNAL OF CONTROLLED RELEASE, 2022, 351 :573-580
[5]   Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2 [J].
Akita, Tomomi ;
Kimura, Ryosuke ;
Akaguma, Saki ;
Nagai, Mio ;
Nakao, Yusuke ;
Tsugane, Mamiko ;
Suzuki, Hiroaki ;
Oka, Jun-ichiro ;
Yamashita, Chikamasa .
JOURNAL OF CONTROLLED RELEASE, 2021, 335 :575-583
[6]   Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems [J].
Alkilani, Ahlam Zaid ;
Nasereddin, Jehad ;
Hamed, Rania ;
Nimrawi, Sukaina ;
Hussein, Ghaid ;
Abo-Zour, Hadeel ;
Donnelly, Ryan F. .
PHARMACEUTICS, 2022, 14 (06)
[7]   A Prospective Analysis of Co-Processed Non-Ionic Surfactants in Enhancing Permeability of a Model Hydrophilic Drug [J].
Alvi, Mohammed M. ;
Chatterjee, Parnali .
AAPS PHARMSCITECH, 2014, 15 (02) :339-353
[8]  
[Anonymous], 2003, CellGate Announces Phase IIa Study Results of PsorBan in the Treatment of Psoriasis
[9]  
[Anonymous], 2023, FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
[10]  
[Anonymous], 2024, MedBroadcast
12345678910